189 related articles for article (PubMed ID: 37056769)
21. Efficacy and safety of transcatheter arterial chemoembolization combined with either
Li Y; Li H; Hu H; Yuan H; Zhao Y
J Cancer Res Ther; 2020; 16(7):1691-1697. PubMed ID: 33565518
[TBL] [Abstract][Full Text] [Related]
22. Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody.
Liu G; Zhou W; Li X; Guo L; He T; Zhao J; Gong L
Front Immunol; 2021; 12():712351. PubMed ID: 34504494
[TBL] [Abstract][Full Text] [Related]
23. Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis.
Jeong SW; Jang JY; Shim KY; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim KH; Kim JH
Gut Liver; 2013 Nov; 7(6):696-703. PubMed ID: 24312711
[TBL] [Abstract][Full Text] [Related]
24. Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Kim JY; Yoo EJ; Jang JW; Kwon JH; Kim KJ; Kay CS
Radiat Oncol; 2013 Jan; 8():15. PubMed ID: 23324259
[TBL] [Abstract][Full Text] [Related]
25. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
[TBL] [Abstract][Full Text] [Related]
26. Programmed cell death protein 1 (PD-1)-inhibition in hepatocellular carcinoma (HCC): a single center experience.
Mahn R; Vogt A; Kupczyk P; Sadeghlar F; van Beekum K; Hüneburg R; Meyer C; Toma M; Ahmadzadehfar H; Essler M; Matthaei H; Lingohr P; Kalff JC; Strassburg CP; Gonzalez-Carmona MA
Scand J Gastroenterol; 2020 Sep; 55(9):1057-1062. PubMed ID: 32692941
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma.
Dai L; Cai X; Mugaanyi J; Liu Y; Mao S; Lu C; Lu C
Sci Rep; 2021 Oct; 11(1):19711. PubMed ID: 34611195
[TBL] [Abstract][Full Text] [Related]
28. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
29. Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Yamamoto Y; Ikoma H; Morimura R; Shoda K; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Kubota T; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Sakakura C; Ochiai T; Otsuji E
World J Gastroenterol; 2015 Jan; 21(1):246-53. PubMed ID: 25574098
[TBL] [Abstract][Full Text] [Related]
30. Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients.
Sun X; Mei J; Lin W; Yang Z; Peng W; Chen J; Zhang Y; Xu L; Chen M
BMC Cancer; 2021 Jul; 21(1):775. PubMed ID: 34218801
[TBL] [Abstract][Full Text] [Related]
31. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
Front Immunol; 2021; 12():794099. PubMed ID: 34950153
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection.
Fu YP; Yi Y; Huang JL; Jing CY; Sun J; Ni XC; Lu ZF; Cao Y; Zhou J; Fan J; Qiu SJ
Oncologist; 2017 May; 22(5):561-569. PubMed ID: 28438885
[TBL] [Abstract][Full Text] [Related]
33. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis.
Liu M; Shi J; Mou T; Wang Y; Wu Z; Shen A
J Gastroenterol Hepatol; 2020 Aug; 35(8):1277-1287. PubMed ID: 32052876
[TBL] [Abstract][Full Text] [Related]
34. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
[TBL] [Abstract][Full Text] [Related]
35. Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.
Grecea M; Marabelle A; Ammari S; Massard C; Champiat S
Oncologist; 2020 May; 25(5):369-374. PubMed ID: 32091646
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
37. C-Reactive Protein Levels Predict Responses to PD-1 Inhibitors in Hepatocellular Carcinoma Patients.
Zhang Y; Lu L; He Z; Xu Z; Xiang Z; Nie RC; Lin W; Chen W; Zhou J; Yin Y; Xie J; Zhang Y; Zheng X; Zhu T; Cai X; Li P; Chao X; Cai MY
Front Immunol; 2022; 13():808101. PubMed ID: 35185894
[TBL] [Abstract][Full Text] [Related]
38. Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials.
Zeng L; Su J; Qiu W; Jin X; Qiu Y; Yu W
Cancer Control; 2022; 29():10732748221092924. PubMed ID: 35418272
[TBL] [Abstract][Full Text] [Related]
39. Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma.
Toya R; Murakami R; Baba Y; Nishimura R; Morishita S; Ikeda O; Kawanaka K; Beppu T; Sugiyama S; Sakamoto T; Yamashita Y; Oya N
Radiother Oncol; 2007 Sep; 84(3):266-71. PubMed ID: 17716760
[TBL] [Abstract][Full Text] [Related]
40. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
